| Trial Identifier: | 214144 |
| Sponsor: | GlaxoSmithKline |
| Start Date: | January 2023 |
| Primary Completion Date: | February 2024 |
| Study Completion Date: | February 2024 |
For questions about your Trial Results Summary, please see Sponsor contact section within your Trial Results Summary.
| Language | Description |
| Country | Location |
|---|---|
| Japan | Chiba, Japan, 263-0043 |
| Japan | Chiba, Japan, 270-0034 |
| Japan | Chiba, Japan, 272-0107 |
| Japan | Chiba, Japan, 286-0201 |
| Japan | Fukuoka, Japan, 810-0001 |
| Japan | Fukuoka, Japan, 811-0120 |
| Japan | Fukuoka, Japan, 814-0013 |
| Japan | Fukuoka, Japan, 816-0943 |
| Japan | Gunma, Japan, 370-0826 |
| Japan | Hokkaido, Japan, 006-0816 |
| Japan | Ibaraki, Japan, 305-0821 |
| Japan | Ibaraki, Japan, 300-0062 |
| Japan | Kagoshima, Japan, 890-0073 |
| Japan | Kanagawa, Japan, 231-0861 |
| Japan | Kanagawa, Japan, 232-0067 |
| Japan | Kochi, Japan, 781-0085 |
| Japan | Miyagi, Japan, 980-0803 |
| Japan | Osaka, Japan, 564-0063 |
| Japan | Osaka, Japan, 534-0024 |
| Japan | Saga, Japan, 840-0831 |
| Japan | Saitama, Japan, 360-0012 |
| Japan | Saitama, Japan, 352-0001 |
| Japan | Tokyo, Japan, 130-0026 |
| Japan | Tokyo, Japan, 162-0804 |
| Japan | Tokyo, Japan, 167-0051 |
| Japan | Tokyo, Japan, 175-0093 |
| Japan | Tokyo, Japan, 186-0002 |